Stem Cell Index Down 1% in Past Week
By Mike Havrilla on 2/9/09
ETF Innovators, LLP
The table at my website link below includes 29 companies in the ETF Innovators (ETFI) Emerging Stem Cell Index, which lost about 1% of market value in the past week and posted an 8.5% loss over the past year on an equal-weight basis. Results for benchmark indexes and ETFs include gains of 1.5% for SPDR S&P Biotech (XBI) and 1.2% for the ETFI
Cosmetic and Reconstructive Medicine Index and losses of 17.4% for Healthcare Sector SPDR (XLV), 3.7% for iShares Nasdaq Biotech (IBB), and 14.5% for PowerShares Biotech & Genome (PBE).
The next catalyst expected for stem cell and regenerative medicine companies is federal funding for stem cell research, which has been blocked by the previous administration for the past eight years. Look for an announcement and upside catalyst once the stimulus and bank rescue plans are finalized.
Today's feature stock from the index is Cord Blood America (OTC: CBAI), which preserves umbilical cord blood stem cells through a quick and non-invasive procedure at the time of birth. CBAI is focused on marketing initiatives to increase
awareness of their services , which literally represent a once in a lifetime opportunity to collect and preserve cord blood stem cells which can be used in the future to treat dozens of conditions with the promise of even more medical breakthroughs with the FDA ruling to allow human stem cell testing and pending federal funding for stem cell research.
Stay tuned for more details and web links for a new website for healthcare investors and traders, which is designed to provide users with more features beyond my current blog format. The new site will feature a discussion forum, news feeds, videos, stock commentaries (including multiple contributors), and other unique content – including my FDA and Clinical Trial Calendars.
Below are 14 business and investing website domain names available for sale and development, including three related to stem cells:
$0.9699 (02/09/09)
